ADC Therapeutics SA (ADCT): Cash & Equivalents
$261.34M
As of 2025-12-31
$219.11M
As of 2026-06-30
-7.1%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $261.34M | +4.2% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $250.87M | -10.0% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $278.60M | -14.7% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $326.44M | n/a | 2024-03-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $261.34M | +4.2% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.91M | -2.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $25.94M | +73.7% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $246.96M | +124.5% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $41.32M | -18.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $120.86M | -27.5% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $12.67M | -66.7% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $122.52M | +29.2% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $128.51M | -17.8% |
Compare ADCT, ARCT, ETON, NRIX side by side · Screen every company in Pharmaceutical Preparations ↗